What is the clinical evidence from this study?

Study design: Review. Population: Atrial fibrillation. Intervention: Left atrial appendage closure devices.

What question did this study set out to answer?

To review contemporary evidence, procedural techniques, imaging guidance, and complication profiles across major left atrial appendage closure device platforms in patients with nonvalvular atrial fibrillation.

April 19, 2026SHILAP Revista de lepidopterologíaOpen Access

Left atrial appendage closure devices: a contemporary review of techniques, tips and tricks

View Full Paper

Ask AI

Bookmark

Key result

LAAC prevents NVAF strokes with >95% procedural success but device-related thrombosis remains a complication.

Why the study?

Atrial fibrillation prevalence is rising and thrombus formation in the left atrial appendage drives thromboembolic stroke, making left atrial appendage closure a key focus for stroke prevention.

Key Points

To review contemporary evidence, procedural techniques, imaging guidance, and complication profiles across major left atrial appendage closure device platforms in patients with nonvalvular atrial fibrillation.
Narrative review evaluating device platforms including Amplatzer Amulet, Watchman 2.5, and Watchman FLX/FLX Pro for left atrial appendage closure.
Synthesized data from clinical trials including the Amulet IDE trial and SWISS-APERO trial evaluating procedural workflow, imaging modalities, and complication rates.
Procedural success rates exceed 95% across contemporary platforms, with head-to-head trials showing an identical 5-year annualized ischemic stroke rate of 1.6% per year between Amplatzer Amulet and Watchman 2.5.
The SWISS-APERO trial demonstrated no statistically significant difference in the 3-year composite endpoint between Amplatzer Amulet and Watchman FLX (hazard ratio 0.58; P=0.06).
Reported post-implant complication frequencies include pericardial effusion in 1%–4%, device-related thrombosis in 3%–7%, procedure-related ischemic stroke in 0.1%–0.6%, and peri-device leaks in 11% to over 50% of cases.

Structured PICO

Population

Adults with nonvalvular atrial fibrillation at risk for thromboembolic stroke

Intervention

Left atrial appendage closure using devices such as Amplatzer Amulet, Watchman 2.5, and Watchman FLX/FLX Pro

This contemporary review highlights that left atrial appendage closure is a highly successful (>95%) and increasingly safe strategy for stroke prevention in nonvalvular atrial fibrillation, with ongoing advancements in device design and post-procedural care.

Limitations

Device-related thrombosis remains an unresolved risk even with newer-generation devices.
Peri-device leak and residual LAA patency present diagnostic and prognostic challenges.
Post-implant antithrombotic regimens lack consensus.
Lack of randomized clinical trial data for the use of devices in patients with valvular atrial fibrillation.
Achieving accurate device sizing remains a persistent challenge.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Warrants LAA closure consideration in select AF patients intolerant to anticoagulation; reinforces its role in reducing thromboembolic risk as prevalence rises.

Cite This Study

Namjouyan et al. (2026) conducted a review in Atrial fibrillation. Left atrial appendage closure devices was evaluated. Left atrial appendage closure devices provide effective stroke prevention in nonvalvular atrial fibrillation with procedural success rates exceeding 95%, though complications like device-related thrombosis remain.

synapsesocial.com/papers/69e470a4010ef96374d8d7e4 https://doi.org/10.3389/fcvm.2026.1767568

Topics

Left atrial appendage closure Persistent AF management Atrial fibrillation Anticoagulation in AF AF ablation outcomes

View Full Paper

Ask AI

Bookmark

Implication

Warrants LAA closure consideration in select AF patients intolerant to anticoagulation; reinforces its role in reducing thromboembolic risk as prevalence rises.